CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - AGENUS INC

Explicit Guidance:

• No formal financial guidance (revenue, earnings, margins, capex, etc.) is provided for any specific future period.
• Financing Triggers: Anticipated receipt of $85 million in additional proceeds if all warrants are exercised, triggered upon enrollment of the 60th patient, expected in Q2 2027.

Business-Segment Outlook:

• Strategic Focus Shift: Full concentration on the neoadjuvant Phase 3 ROBIN trial for high-risk stage II/III MSS colon cancer as the sole registration and enabling trial.
• Trial Endpoints & Timelines:
  • First Patient Enrollment: Expected in Q1 2027.
  • Interim Pathologic Response Data: Anticipated in Q4 2027 (based on the first 100 patients; 50 treated, 50 control). This serves as a confidence generator but is not a regulatory go/no-go milestone.
  • Interim Event-Free Survival (EFS): Expected in H2 2029 (75% information fraction).
  • Final EFS Analysis: Anticipated in H2 2030.
• Current Operations: Continued patient access via compassionate use programs in ~30 countries and reimbursement in France for late-line refractory MSS colorectal, sarcoma, and ovarian cancers.
• Backlog/Portfolio: BATMAN (late-line MSS) program funding halted; focus shifted entirely to ROBIN. NEST and Unicorn neoadjuvant data published with >2–3 years maturity showing 0% recurrence vs. ~25% historical recurrence.

Market and Competitive Outlook:

• Market Size: U.S. newly diagnosed MSS patient population estimated at 30,000 annually, with a potential annual sales opportunity of $7 billion if the ROBIN trial succeeds.
• Competitive Landscape: Management views the dMMR neoadjuvant setting as "settled" (citing nivolumab/ipilimumab data) and believes current resources are better allocated to the unmet need in MSS where standard of care (surgery/chemo) has high recurrence rates.
• Adoption Drivers: Expectation that interim 2027 pathologic response data (aiming for 40-50% rates) will rapidly accelerate patient and investigator enrollment once demonstrated.
• De-escalation Trend: Anticipated reduction in chemotherapy, radiation, and mutilating surgeries (e.g., ostomies) if ROBIN outcomes confirm reduced recurrence and high event-free survival.

Macro / Industry Outlook:

• Regulatory Pathway: No comment on "accelerated approval" strategies; focus remains on standard Phase 3 endpoints to secure full approval.
• External Authorizations: Marketing authorization in Armenia and reimbursement in France serve as validation of demand and clinical utility but are not primary revenue drivers.
• Economic/Resource Constraints: Management explicitly cites the "bandwidth and resource" challenges for small/mid-cap biotechs in running multiple global Phase 3 trials simultaneously as a key factor in the strategic pivot.

Strategic Initiatives:

• Phase 3 ROBIN Trial: Execution of the sole registration trial to establish efficacy in the neoadjuvant MSS setting.
• Data Catalysts: Presentation of NEST and dMMR neoadjuvant data at ESMO Madrid; submission of long-term survival data and Agent-T797 combination work at ASCO (early November); publication of NEST and Unicorn manuscripts in the coming months.
• Enrollment Strategy: Aiming for a "slow start" followed by a "massive ramp-up" contingent on the release of interim 2027 pathologic response data to alleviate physician skepticism regarding long-term efficacy.

Risks and Headwinds to Outlook:

• Trial Failure: The primary risk is the ROBIN trial not reading out positively (failing to show a significant reduction in recurrence rates or a hazard ratio of ≤0.65).
• Enrollment Challenges: Initial difficulty in recruiting patients due to the recent termination of the BATMAN program, which caused disappointment among investigators and sites ("gut-wrenching" reaction).
• Caveats on Efficacy: While NEST/Unicorn data show no recurrence, management notes that a lack of recurrence does not definitively prove a "cure" given the relatively small sample size and high standards for confirming long-term survival.
• Timeline Ambition: Management acknowledges the enrollment timeline may be "too ambitious" and anticipates a slower start before the ramp-up.

Management Tone on the Future:

• Confidence: High degree of confidence that the ROBIN trial will read out positively; management states, "We have a strong degree of confidence that it will."
• Sentiment: Cautiously optimistic regarding the biological rationale and the potential to "drive higher event-free survival" and de-escalate toxic treatments.
• Shift in Perspective: Management acknowledges the difficult decision to pivot was necessary due to resource constraints but emphasizes a belief that the earlier setting offers the "most profound impact on patients."
• Investor Relations: Designed financing to align closely with the trial's value inflection points (Q2 2027 warrant trigger, Q4 2027 data readout).

Miscellaneous:

• Hazard Ratio Target: Management anticipates exceeding a hazard ratio of 0.65 (35% improvement in recurrence) and potentially seeing maintenance of ctDNA negativity, which is viewed as the best predictor of long-term survival.
• Safety Profile: Expected to maintain <5% Grade 3/4 adverse events manageable in the clinic.
• Future Research: Exploration of Agent T-797 combination data and long-term survival updates remains a priority alongside the ROBIN trial.